The efficacy of nivolumab (anti-PD-1) in combination with ipilimumab (anti-CTLA-4) in the treatment of melanoma or metastatic or recurrent non-small cell lung cancer (NSCLC), in the latter case also with platinum-doublet chemotherapy, has also been demonstrated (97). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.